HDB focuses on drug discovery biology and aligned its core competence and capabilities with integrated structure activity relationship (SAR) research. The plate-based pharmacological and screening platforms are fully implemented to help client speed up the process of hit identification, compound profiling, early compound safety assessment, and in vitro efficacies. Our experienced experts offer streamline processes from stable/transient cell line development, protein/enzyme provision, de novo assay development/optimization and validation, to compound logistic and compound screening, as well as data analysis/management. The implementation of process with QCs and the state-of-the-Art infrastructures enable our seamless delivery of projects that contribute to SAR and early drug discovery. Furthermore, HDB’s competences in in vivo efficacy studies, in vivo/in vitro Absorption, Distribution, Metabolism, and Excretion (ADME) screening, toxicity studies would accelerate the process of preclinical study from lead identification to optimization in drug development. Emphasis on scientific inputs, innovated technologies/efficient process, and the quality of the services, has earned HDB an exceptional reputation in the CRO industry.